Linezolid for resistant Gram-positive bacterial infections in children under 12 years: A meta-analysis

Wu Qian; Xu Xiaohua; Tian Mingqing; Jiang Jianyang

doi:10.1515/med-2022-0440

Open Medicine (May 2022)

Linezolid for resistant Gram-positive bacterial infections in children under 12 years: A meta-analysis

Wu Qian,
Xu Xiaohua,
Tian Mingqing,
Jiang Jianyang

Affiliations

Wu Qian: Department of Respiratory and Critical Care Medicine, People’s Hospital of Quzhou, Quzhou 324000, Zhejiang Province, China
Xu Xiaohua: Department of Respiratory and Critical Care Medicine, People’s Hospital of Quzhou, Quzhou 324000, Zhejiang Province, China
Tian Mingqing: Department of Respiratory and Critical Care Medicine, People’s Hospital of Quzhou, Quzhou 324000, Zhejiang Province, China
Jiang Jianyang: Department of Respiratory and Critical Care Medicine, People’s Hospital of Quzhou, Quzhou 324000, Zhejiang Province, China

DOI: https://doi.org/10.1515/med-2022-0440
Journal volume & issue: Vol. 17, no. 1
pp. 969 – 977

Abstract

Read online

Both linezolid and vancomycin have good efficacy in the treatment of resistant Gram-positive bacterial infections. This systematic review and meta-analysis aimed to compare the efficacy and safety of linezolid vs vancomycin for the treatment of resistant Gram-positive bacterial infections in children under 12 years.

Published in Open Medicine

ISSN: 2391-5463 (Online)
Publisher: De Gruyter
Country of publisher: Poland
LCC subjects: Medicine
Website: https://www.degruyter.com/journal/key/med/html

About the journal

Abstract

Keywords